Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS, AZ’s Combo Diabetes Drug Gains Approval | Contract Pharma

What are you searching for?

Sign in

BMS, AZ’s Combo Diabetes Drug Gains Approval

Bristol-Myers Squibb and AstraZeneca received approval from the FDA for Kombiglyze XR for the treatment of type 2 diabetes in adults.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and AstraZeneca received approval from the FDA for Kombiglyze XR for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering glycemic control across glycosylated hemoglobin levels (HbA1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG).

Kombiglyze XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. The approval was based on two Phase III trials and bioequivalence studies that evaluated the efficacy and safety of saxagliptin and metformin IR as separate tablets compared to placebo added to metformin IR. Bioequivalence was demonstrated in healthy adults between Kombiglyze XR and saxagliptin plus metformin XR as separate tablets.

“Nearly half of adult patients remain uncontrolled on their current treatment regimen and may thus require additional medications,” said Elliott Sigal, M.D., Ph.D, executive vice president, chief scientific officer, and president, R&D, BMS. “With our heritage of bringing metformin — the most widely prescribed oral antidiabetic medication — and more recently saxagliptin to patients in the U.S., we are committed to making Kombiglyze XR the newest building block in our long-term commitment to helping adult patients with type 2 diabetes.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters